New Zealand markets closed

Aridis Pharmaceuticals, Inc. (ARDS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4100+0.0469 (+12.92%)
At close: 04:00PM EDT
0.4255 +0.02 (+3.78%)
After hours: 06:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3631
Bid0.0000 x 1000
Ask0.0000 x 1200
Day's range0.3600 - 0.4289
52-week range0.3500 - 2.7700
Avg. volume1,648,663
Market cap14.792M
Beta (5Y monthly)1.07
PE ratio (TTM)N/A
EPS (TTM)-1.7500
Earnings date29 Mar 2023 - 03 Apr 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.00
  • GlobeNewswire

    Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock

    Los Gatos, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,000,000 shares of the Company’s common stock at a purchase price of $0.38 per share in a registered direct offering. The closing of the offering is expected to occur on or about March 16, 2023, subject to the satisfaction of customary closing conditions. H.C. W

  • GlobeNewswire

    Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients

    The study achieved high uptake of AR-501 in the respiratory tract at levels that were more than 50-fold higher than required for inhibition of the target bacteria P. aeruginosa LOS GATOS, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced preliminary top-line results from the randomized, double blinded, placebo-controlled Phase 2a study of AR-501, which evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as

  • Simply Wall St.

    When Will Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Breakeven?

    With the business potentially at an important milestone, we thought we'd take a closer look at Aridis Pharmaceuticals...